A Phase 2 interventional study of Placebo and TAK-101 in Celiac Disease, sponsored by Takeda. Completed at 48 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Takeda · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 20th largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2022, is one of 21 in phase 2, and was the 73rd registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Joined Bio · Sites in United States
Ages 18–90 · Healthy volunteers
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 50 across 215 interventional studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
Takeda has 6 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD).
Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All participants will receive active treatment at Week 24.
The drug being tested in this study is called TAK-101. TAK-101 is being tested to treat people who have celiac disease. The study has 2 cohorts planned. Cohort 1 has 1 dose level and the Cohort 2 may include 1 or 2 additional dose levels, depending on safety, tolerability, and activity observed in Cohort 1. Dosing in the Cohort 2 will be based on data from Cohort 1.
The study will enroll approximately 90 patients. In Cohort 1, approximately 45 participants will be randomly assigned in 1:2:2 ratio in one of the three arm groups which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need). Eligible participants in Cohort 1 will receive:
If it is deemed appropriate to enroll both the TAK-101 50 µg/kg GE and the 12.5 µg/kg GE dose levels in Cohort 2, approximately 45 participants may be randomly assigned in 1:2:2 ratio in Cohort 2 to receive:
If it is decided not to open the second cohort at the 50 µg/kg GE dose level and if 12.5 µg/kg GE dose is recommended to be tested by the independent data monitoring committee (IDMC), approximately 27 participants will be randomly assigned in 1:2 ratio to receive:
This trial will be conducted globally. The overall time to participate in this study is approximately 34 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone OR plus a final visit after receiving their last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-confirmed CeD that is well-controlled, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD and with immunoglobulin A (IgA) tissue transglutaminase (tTG) \<2 × (ULN) and IgG deamidated gliadin peptide (DGP) \<3 × ULN.
Note: Participants may be retested for IgA tTG and IgG DGP to meet eligibility criteria at the discretion of the investigator. Intermittent symptoms would not exclude participants from participation as long as symptoms are generally well controlled in the opinion of the investigator, and as long as symptoms are back to baseline for 2 weeks before the run-in gluten challenge.
Exclusion Criteria:
Has presence of other inflammatory gastrointestinal (GI) disorders or systemic diseases, that either have the potential to cause persistent GI symptoms similar to CeD or are not well controlled without the use of excluded medications.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 matching placebo intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 microgram per kilogram (µg/kg) GE will be given 23 weeks after the second dose at approximately Week 24.
Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg, IV infusion once on Day 1 followed by TAK-101 matching placebo IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.
Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.
Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 matching placebo IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 50 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 50 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open Cohort 2 at the 50 µg/kg GE dose level.
Drug: Placebo · Drug: TAK-101 · Dietary Supplement: Gluten
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 12.5 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
Drug: TAK-101 · Dietary Supplement: Gluten
TAK-101 matching placebo intravenous infusion
TAK 101 intravenous infusion
Powder form (vital wheat gluten)
Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay
IFN-γ SFUs were measured based on results of a gliadin-specific ELISpot assay using peripheral blood mononuclear cells (PBMCs). Gliadin-specific cluster of differentiation 4 (CD4) T cells were a small percentage of the PBMCs and responded to gliadin peptide stimulation in vitro by producing the IFN-γ cytokine. Baseline was defined as Day 15.
Time frame: Baseline (Day 15), Week 3 (Day 20)
Percentage of Participants Experiencing at Least One Treatment-emergent Adverse Event (TEAE) and Adverse Events of Special Interest (AESIs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started, or severity worsened, or intensity increased after receiving the first study drug administration and up to within 30 days of last dose of study drug. An AESI (serious or nonserious) is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate. AESIs are reported based on the Standardized MedDRA Queries (SMQs) and based on case report forms (CRFs).
Time frame: Up to Week 28
Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change of the 3-day Average Nausea Severity Score as Measured in Celiac Disease Symptom Diary (CDSD)
CDSD version 2.1 is a 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of available daily scores recorded in 3 days prior and after the respective gluten challenge. Results are reported as least squares (LS) mean change from run-in at Weeks 8, 14 and 20, determined using a linear mixed-effect model for repeated measures (MMRM) analysis. A negative change from run-in indicates improvement.
Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Change From Run-in (Visit 2) to Weeks 8,14, and 20 in the Pre- to Post-gluten Challenge Change in CDSD 3-day Peak Nausea Severity Score
CDSD version 2.1 is an 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of the available daily scores recorded in the 3 days prior and after the respective gluten challenge. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.
Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Change From Run-in (Visit 2) to Weeks 8, 14, and 20 in the Pre- to Post-gluten Challenge Change in Weekly Gastrointestinal (GI) Symptom Severity Score
CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the week. The daily GI symptom severity score is the average of the severity score for diarrhea, abdominal pain, bloating and nausea, ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.
Time frame: Run-in (Visit 2 at Week -4), Weeks 8, 14, and 20
Fold Change in Plasma Interleukin-2 (IL-2) From Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20
The pre-gluten to 4 hours post-gluten challenge log transformed fold change in plasma IL-2 from Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20 were compared. Results are reported as LS mean change from run-in at Day 15, Weeks 8, 14 and 20, determined using a linear MMRM analysis.
Time frame: Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
Fold Change in Plasma IL-2 at Specified Time Points
The pre-gluten to 4 hours post-gluten challenge log-transformed fold change in plasma IL-2 at each of the time points is reported.
Time frame: Run-in (Visit 2 at Week -4), Week 2 (Day 15), and Weeks 8, 14, and 20
Plasma Concentration of TAK-101 After Each Dose
Free gliadin concentration in the plasma was measured and reported.
Time frame: At end of infusion of Weeks 0, 1 and 24
Serum Concentration of Antidrug Antibody (ADAs) to Various Doses of TAK-101
ADA includes deamidated gliadin peptide- immunoglobulin G (DGP- IgG). Serum Concentration of ADAs was measured in Enzyme-Linked ImmunoAssay Units per milliliter denoted as EliA U/mL.
Time frame: Predose at Weeks 1 and 24; and before gluten challenge at Weeks 2, 14, and 20
Participants took part in the study at various investigative sites globally from 23 June 2022 to 08 January 2026.
| Milestone | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Started | 22 | 20 | 21 | 20 | 19 |
| Completed | 21 | 18 | 19 | 17 | 16 |
| Not completed | 1 | 2 | 2 | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 | 2 |
| Withdrew: Reason not specified | 0 | 1 | 1 | 1 | 1 |
IFN-γ SFUs were measured based on results of a gliadin-specific ELISpot assay using peripheral blood mononuclear cells (PBMCs). Gliadin-specific cluster of differentiation 4 (CD4) T cells were a small percentage of the PBMCs and responded to gliadin peptide stimulation in vitro by producing the IFN-γ cytokine. Baseline was defined as Day 15.
| SFUs/10^6 cells PBMC | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Baseline | 2.2 ± 4.25 | 2.4 ± 4.61 | 1.9 ± 2.50 | 3.8 ± 5.24 | 3.9 ± 5.11 |
| Change at Day 20 | 4.0 ± 14.39 | 1.3 ± 5.43 | 3.3 ± 8.77 | 3.3 ± 10.29 | -0.3 ± 5.70 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started, or severity worsened, or intensity increased after receiving the first study drug administration and up to within 30 days of last dose of study drug. An AESI (serious or nonserious) is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate. AESIs are reported based on the Standardized MedDRA Queries (SMQs) and based on case report forms (CRFs).
| percentage of participants | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Any TEAE | 81.8 | 94.7 | 85.7 | 95.0 | 84.2 |
| AESI CRF | 4.5 | 21.1 | 14.3 | 15.0 | 42.1 |
| AESI SMQ | 4.5 | 21.1 | 23.8 | 20.0 | 36.8 |
CDSD version 2.1 is a 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of available daily scores recorded in 3 days prior and after the respective gluten challenge. Results are reported as least squares (LS) mean change from run-in at Weeks 8, 14 and 20, determined using a linear mixed-effect model for repeated measures (MMRM) analysis. A negative change from run-in indicates improvement.
| score on a scale | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 8 | -0.190 (-0.474 to 0.094) | -0.081 (-0.357 to 0.195) | -0.345 (-0.630 to -0.060) | -0.017 (-0.358 to 0.324) | -0.428 (-0.744 to -0.113) |
| Week 14 | -0.258 (-0.565 to 0.049) | -0.196 (-0.471 to 0.080) | -0.237 (-0.500 to 0.026) | -0.136 (-0.477 to 0.204) | -0.222 (-0.525 to 0.081) |
| Week 20 | -0.303 (-0.587 to -0.020) | -0.128 (-0.427 to 0.170) | -0.443 (-0.711 to -0.174) | -0.151 (-0.634 to 0.333) | -0.213 (-0.517 to 0.091) |
CDSD version 2.1 is an 8-item (severity of diarrhea, abdominal pain, bloating, nausea, and tiredness, frequency of bowel movement and vomiting, and a count of loosest stool forms), self-administered questionnaire that evaluates CeD symptoms using 5-point Likert-type scales (\[0\] none, \[1\] mild, \[2\] moderate, \[3\] severe, and \[4\] very severe), where lower score indicating no symptoms and higher score indicating severe symptoms for all items except for frequency questions relating to stool counts, diarrhea, and vomiting frequency. Scores from past 3 days with a 24-hour recall period were averaged. For Run-in, Weeks 8, 14, and 20, each score was calculated as average of the available daily scores recorded in the 3 days prior and after the respective gluten challenge. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.
| score on a scale | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 8 | -0.024 (-0.502 to 0.453) | 0.077 (-0.390 to 0.544) | -0.347 (-0.828 to 0.133) | 0.007 (-0.514 to 0.527) | -0.595 (-1.088 to -0.103) |
| Week 14 | -0.363 (-0.830 to 0.103) | -0.063 (-0.540 to 0.414) | -0.447 (-0.904 to 0.010) | 0.064 (-0.486 to 0.615) | -0.195 (-0.688 to 0.297) |
| Week 20 | -0.637 (-1.115 to -0.159) | -0.008 (-0.463 to 0.446) | -0.656 (-1.113 to -0.200) | -0.074 (-0.674 to 0.527) | -0.262 (-0.754 to 0.230) |
CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the week. The daily GI symptom severity score is the average of the severity score for diarrhea, abdominal pain, bloating and nausea, ranging from 0 to 4. Symptom severity is evaluated using 5-point Likert-type scales (none, mild, moderate, severe, and very severe). Higher scores indicate more severe symptoms. Results are reported as LS mean change from run-in at Weeks 8, 14 and 20, determined using a linear MMRM analysis. A negative change from run-in indicates improvement.
| score on a scale | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 8 | -0.067 (-0.212 to 0.077) | -0.035 (-0.168 to 0.098) | -0.155 (-0.297 to -0.013) | -0.112 (-0.266 to 0.042) | -0.092 (-0.236 to 0.053) |
| Week 14 | -0.117 (-0.257 to 0.022) | 0.064 (-0.076 to 0.204) | -0.093 (-0.231 to 0.045) | -0.173 (-0.337 to -0.009) | -0.122 (-0.271 to 0.027) |
| Week 20 | -0.213 (-0.353 to -0.073) | 0.028 (-0.105 to 0.161) | -0.159 (-0.300 to -0.018) | -0.187 (-0.367 to -0.006) | -0.061 (-0.206 to 0.083) |
The pre-gluten to 4 hours post-gluten challenge log transformed fold change in plasma IL-2 from Run-in (Visit 2) to Day 15, and Weeks 8, 14, and 20 were compared. Results are reported as LS mean change from run-in at Day 15, Weeks 8, 14 and 20, determined using a linear MMRM analysis.
| log (fold change) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 2 | 1.013 (0.491 to 1.535) | 1.121 (0.565 to 1.678) | 0.600 (0.076 to 1.124) | 1.757 (1.199 to 2.315) | 0.723 (0.141 to 1.305) |
| Week 8 | -0.322 (-0.861 to 0.216) | -0.247 (-0.814 to 0.320) | -0.805 (-1.329 to -0.281) | -0.551 (-1.137 to 0.034) | -0.891 (-1.487 to -0.296) |
| Week 14 | -0.289 (-0.819 to 0.240) | -0.430 (-0.986 to 0.126) | -0.521 (-1.073 to 0.030) | 0.422 (-0.168 to 1.011) | -0.688 (-1.283 to -0.094) |
| Week 20 | -0.475 (-1.004 to 0.054) | -0.593 (-1.149 to -0.037) | -0.644 (-1.194 to -0.095) | 0.043 (-0.571 to 0.657) | -0.503 (-1.110 to 0.103) |
The pre-gluten to 4 hours post-gluten challenge log-transformed fold change in plasma IL-2 at each of the time points is reported.
| log (fold change) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Run-in (Week -4) | 2.15 ± 1.435 | 2.12 ± 1.425 | 2.47 ± 1.947 | 2.58 ± 1.894 | 1.75 ± 2.067 |
| Week 2 | 3.16 ± 1.359 | 3.26 ± 1.657 | 2.97 ± 1.600 | 4.16 ± 2.310 | 2.54 ± 2.046 |
| Week 8 | 1.82 ± 1.195 | 1.97 ± 0.989 | 1.56 ± 1.305 | 1.93 ± 2.240 | 1.00 ± 1.424 |
| Week 14 | 1.78 ± 1.326 | 1.71 ± 1.450 | 1.87 ± 1.680 | 2.50 ± 1.829 | 1.21 ± 1.512 |
| Week 20 | 1.63 ± 1.403 | 1.54 ± 1.068 | 1.76 ± 1.288 | 2.10 ± 1.779 | 1.31 ± 1.433 |
Free gliadin concentration in the plasma was measured and reported.
| nanograms per milliliter (ng/mL) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 0 | NA ± NA | 574.89 ± 104.544 | 551.21 ± 101.606 | 257.45 ± 61.830 | 913.56 ± 261.678 |
| Week 1 | NA ± NA | NA ± NA | 423.79 ± 161.542 | 195.54 ± 78.827 | 848.06 ± 256.314 |
| Week 24 | 585.23 ± 90.526 | 613.72 ± 176.414 | 601.22 ± 142.565 | 289.31 ± 67.812 | 1171.75 ± 157.166 |
ADA includes deamidated gliadin peptide- immunoglobulin G (DGP- IgG). Serum Concentration of ADAs was measured in Enzyme-Linked ImmunoAssay Units per milliliter denoted as EliA U/mL.
| EliA U/mL | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| Week 1 (Day 8) | 1.86 ± 3.482 | 2.94 ± 3.173 | 3.88 ± 6.732 | 2.75 ± 3.231 | 3.18 ± 4.006 |
| Week 2 (Day 15) | 1.69 ± 2.704 | 3.17 ± 3.369 | 6.98 ± 12.539 | 6.83 ± 8.082 | 12.20 ± 23.588 |
| Week 14 | 2.05 ± 2.842 | 3.72 ± 5.298 | 5.10 ± 8.784 | 11.22 ± 28.126 | 10.63 ± 27.621 |
| Week 20 | 2.30 ± 2.638 | 2.45 ± 3.056 | 5.06 ± 9.144 | 6.17 ± 10.929 | 6.90 ± 15.418 |
| Week 24 | 2.37 ± 2.348 | 3.97 ± 6.428 | 4.57 ± 8.608 | 5.12 ± 9.164 | 4.47 ± 8.632 |
Collected over Up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | 0/22 (0%) | 0/22 (0%) | 17/22 (77.3%) |
| Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | 0/20 (0%) | 0/19 (0%) | 18/19 (94.7%) |
| Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | 0/20 (0%) | 0/20 (0%) | 15/20 (75%) |
| Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE | 0/19 (0%) | 0/19 (0%) | 16/19 (84.2%) |
| Event | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE |
|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 7/22 | 5/19 | 4/21 | 6/20 | 3/19 |
| HEADACHENervous system disorders | 4/22 | 6/19 | 2/21 | 4/20 | 1/19 |
| DIARRHOEAGastrointestinal disorders | 3/22 | 5/19 | 2/21 | 0/20 | 5/19 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 1/22 | 2/19 | 3/21 | 3/20 | 5/19 |
| FATIGUEGeneral disorders | 1/22 | 3/19 | 4/21 | 5/20 | 4/19 |
| THROMBIN-ANTITHROMBIN III COMPLEX INCREASEDInvestigations | 2/22 | 4/19 | 1/21 | 4/20 | 1/19 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 3/22 | 3/19 | 1/21 | 2/20 | 0/19 |
| FIBRIN D DIMER INCREASEDInvestigations | 0/22 | 3/19 | 0/21 | 1/20 | 1/19 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 1/22 | 3/19 | 0/21 | 0/20 | 1/19 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/22 | 3/19 | 2/21 | 3/20 | 1/19 |
All Randomized Set consisted of all the participants who were randomized.
| Age, Continuous(years) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE | Total |
|---|---|---|---|---|---|---|
| Mean | 42.8 ± 12.64 | 46.4 ± 14.63 | 43.1 ± 13.35 | 47.4 ± 11.72 | 41.3 ± 11.84 | 44.2 ± 12.84 |
| Sex: Female, Male(Participants) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 17 | 13 | 9 | 13 | 65 |
| Male | 9 | 3 | 8 | 11 | 6 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 20 | 18 | 20 | 20 | 19 | 97 |
| Unknown or Not Reported | 1 | 1 | 1 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Cohorts 1 and 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE | Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE | Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE | Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 19 | 20 | 21 | 17 | 19 | 96 |
| More than one race | 1 | 0 | 0 | 2 | 0 | 3 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2022 to primary completion in Dec 2025, 41 months.
Results were first posted in Oct 2026, 9 months after primary completion.
Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-101